Tambocor Dispute, FTC Report May Keep Generic Drugs On Congress' Agenda
A dispute between Par and Barr over generic exclusivity for flecainide reflects the continued complexities in the Waxman/Hatch process that could drive Congressional action over the next 18 months.
You may also be interested in...
Par's acquisition of ISP's FineTech chemical business reflects the generic drug company's desire to gain greater control over all aspects of the manufacturing process in the current environment of patent disputes
The Taxol appeals court ruling may make it more difficult for FDA to stray from a "ministerial" approach to "Orange Book" patent listings
Barr will launch Nortrel 7/7/7, its generic of Ortho-McNeil's Ortho-Novum 7/7/7, in January 2003 per an Oct. 29 patent litigation settlement